进展性缺血性脑卒中患者经醒脑静注射液治疗疗效及对NIHSS评分Lp―PLA2水平影响.docVIP

进展性缺血性脑卒中患者经醒脑静注射液治疗疗效及对NIHSS评分Lp―PLA2水平影响 　　【摘要】 目的：研究进展性缺血性脑卒中患者经醒脑静注射液治疗的疗效及对美国国立卫生研究院卒中量表（NIHSS）评分、血浆脂蛋白相关磷脂酶A2（Lp-PLA2）水平的影响。方法：选取2016年1月-2017年1月本院收治的进展性缺血性脑卒中患者96例作为研究对象，并按照随机分组原则将其分为观察组与对照组，各48例。按照进展性缺血性脑卒中的主要危险因素给予对照组常规治疗，观察组则在此基础上给予醒脑静注射液进行治疗。比较两组治疗前后血小板相关指标（血小板聚集率、血小板黏附率）、神经功能缺损程度量表（NDS）评分、NIHSS评分、C反应蛋白（CRP）及血浆Lp-PLA2水平，比较两组临床疗效。结果：观察组总有效率为93.8%，高于对照组的79.2%，比较差异有统计学意义（ 字2=4.359，P=0.037）；治疗后，两组血小板黏附率、血小板聚集率、NDS评分、NIHSS评分、CRP及血浆Lp-PLA2水平均低于治疗前（P0.05），且观察组均低于对照组（P0.05）。结论：醒脑静注射液治疗进展性缺血性脑卒中患者疗效显著，能够显著降低NIHSS量表评分及血浆Lp-PLA2的水平，值得推广应用。 　　【关键词】 醒脑静注射液； 脑卒中； Lp-PLA2； NHISS 　　【Abstract】 Objective：To study the efficacy of Xingnaojing Injection in the treatment of progressive ischemic stroke patients and the influence on National Institutes of Health Stroke Scale（NIHSS） score and plasma lipoprotein associated phospholipase A2（Lp-PLA2） levels.Method：A total of 96 patients with progressive ischemic stroke admitted in our hospital from January 2016 to January 2017 were selected as the research subjects，according to the principle of random grouping，they were divided into observation group and control group，48 cases in each group.The control group was given routine treatment according to the main risk factors in progressive ischemic stroke，and observation group was given Xingnaojing Injection on basis of control group.The platelet related indicators（platelet aggregation rate，platelet adhesion rate），neurological deficit scale（NDS） score，NIHSS score，C reactive protein（CRP） and plasma Lp-PLA2 levels in two groups before and after treatment were compared，and the clinical efficacy of two groups were compared.Result：The total effective rate of observation group was 93.8%，which was higher than 79.2% of control group，the difference was statistically significant（ 字2=4.359，P=0.037）.After treatment，the platelet adhesion rate，platelet aggregation rate，NDS score，NIHSS score，CRP and plasma Lp-PLA2 levels in two groups were all lower than those of before treatment（P0.05），and the obse